{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:33:29Z","timestamp":1782513209196,"version":"3.54.5"},"reference-count":126,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.arbres.2016.07.004","type":"journal-article","created":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T02:47:24Z","timestamp":1473648444000},"page":"19-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Tratamiento antigripal: f\u00e1rmacos actualmente utilizados y nuevos agentes en desarrollo"],"prefix":"10.1016","volume":"53","author":[{"given":"Luciano","family":"Amarelle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Lecuona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob I.","family":"Sznajder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2016.07.004_bib0635","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(99)01241-6","article-title":"Influenza","volume":"354","author":"Cox","year":"1999","journal-title":"Lancet."},{"key":"10.1016\/j.arbres.2016.07.004_bib0640","first-page":"630","article-title":"Clinical diagnosis of influenza virus infection: Evaluation of diagnostic tools in general practice","volume":"51","author":"Van Elden","year":"2001","journal-title":"Br J Gen Pract."},{"key":"10.1016\/j.arbres.2016.07.004_bib0645","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa0906612","article-title":"Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China","volume":"361","author":"Cao","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arbres.2016.07.004_bib0650","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa0906695","article-title":"Hospitalized patients with 2009 H1N1 influenza in the United States, april-june 2009","volume":"361","author":"Jain","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arbres.2016.07.004_bib0655","unstructured":"World Health Organization. Influenza (seasonal). Fact sheet No 211, March 2014. Disponible en: www.who.int\/mediacentre\/factsheets\/fs211\/en\/"},{"key":"10.1016\/j.arbres.2016.07.004_bib0660","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.3390\/v7092850","article-title":"Clinical implications of antiviral resistance in influenza","volume":"7","author":"Li","year":"2015","journal-title":"Viruses."},{"key":"10.1016\/j.arbres.2016.07.004_bib0665","first-page":"1","article-title":"Antiviral agents for the treatment and chemoprophylaxis of influenza --- Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","author":"Fiore","year":"2011","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.arbres.2016.07.004_bib0670","doi-asserted-by":"crossref","first-page":"e0136186","DOI":"10.1371\/journal.pone.0136186","article-title":"Clinical characteristics are similar across type A and B influenza virus infections","volume":"10","author":"Mosnier","year":"2015","journal-title":"PLoS One."},{"key":"10.1016\/j.arbres.2016.07.004_bib0675","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/bmj.4.5624.153","article-title":"Production of common colds in human volunteers by influenza C virus","volume":"4","author":"Joosting","year":"1968","journal-title":"Br Med J."},{"key":"10.1016\/j.arbres.2016.07.004_bib0680","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/jmv.23756","article-title":"Influenza C virus infection in military recruits--Symptoms and clinical manifestation","volume":"86","author":"Kauppila","year":"2014","journal-title":"J Med Virol."},{"key":"10.1016\/j.arbres.2016.07.004_bib0685","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0042-6822(76)90355-X","article-title":"Polypeptides specified by the influenza virus genome: I. Evidence for eight distinct gene products specified by fowl plague virus","volume":"74","author":"Inglis","year":"1976","journal-title":"Virology."},{"key":"10.1016\/j.arbres.2016.07.004_bib0690","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/0042-6822(70)90337-5","article-title":"Influenza virus proteins. I. Analysis of polypeptides of the virion and identification of spike glycoproteins","volume":"42","author":"Compans","year":"1970","journal-title":"Virology."},{"key":"10.1016\/j.arbres.2016.07.004_bib0695","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/0042-6822(71)90270-4","article-title":"The polypeptide composition of influenza A viruses","volume":"44","author":"Skehel","year":"1971","journal-title":"Virology."},{"key":"10.1016\/j.arbres.2016.07.004_bib0700","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1038\/ncomms5816","article-title":"Conserved and host-specific features of influenza virion architecture","volume":"5","author":"Hutchinson","year":"2014","journal-title":"Nat Commun."},{"key":"10.1016\/j.arbres.2016.07.004_bib0705","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1073\/pnas.73.9.3045","article-title":"Influenza virus genome consists of eight distinct RNA species","volume":"73","author":"McGeoch","year":"1976","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.arbres.2016.07.004_bib0710","article-title":"Orthomyxoviridae","volume":"1","author":"Shaw","year":"2013"},{"key":"10.1016\/j.arbres.2016.07.004_bib0715","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/333426a0","article-title":"Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid","volume":"333","author":"Weis","year":"1988","journal-title":"Nature."},{"key":"10.1016\/j.arbres.2016.07.004_bib0720","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0168-1702(93)90056-S","article-title":"Influenza virus strains selectively recognize sialyloligosaccharides on human respiratory epithelium; the role of the host cell in selection of hemagglutinin receptor specificity","volume":"29","author":"Couceiro","year":"1993","journal-title":"Virus Res."},{"key":"10.1016\/j.arbres.2016.07.004_bib0725","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1465-9921-8-73","article-title":"Sialic acid receptor detection in the human respiratory tract: Evidence for widespread distribution of potential binding sites for human and avian influenza viruses","volume":"8","author":"Nicholls","year":"2007","journal-title":"Respir Res."},{"key":"10.1016\/j.arbres.2016.07.004_bib0730","doi-asserted-by":"crossref","first-page":"9896","DOI":"10.1128\/JVI.01118-06","article-title":"Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium","volume":"80","author":"B\u00f6ttcher","year":"2006","journal-title":"J Virol."},{"key":"10.1016\/j.arbres.2016.07.004_bib0735","doi-asserted-by":"crossref","first-page":"e1003774","DOI":"10.1371\/journal.ppat.1003774","article-title":"Tmprss2 is essential for influenza H1N1 virus pathogenesis in mice","volume":"9","author":"Hatesuer","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.arbres.2016.07.004_bib0740","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1073\/pnas.79.4.968","article-title":"Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion","volume":"79","author":"Skehel","year":"1982","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.arbres.2016.07.004_bib0745","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/j.1460-2075.1982.tb01150.x","article-title":"Membrane fusion activity of influenza virus","volume":"1","author":"White","year":"1982","journal-title":"EMBO J."},{"key":"10.1016\/j.arbres.2016.07.004_bib0750","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1083\/jcb.89.3.674","article-title":"Cell fusion by Semliki Forest, influenza, and vesicular stomatitis viruses","volume":"89","author":"White","year":"1981","journal-title":"J Cell Biol."},{"key":"10.1016\/j.arbres.2016.07.004_bib0755","doi-asserted-by":"crossref","first-page":"8391","DOI":"10.1128\/JVI.70.12.8391-8401.1996","article-title":"Effect of M1 protein and low pH on nuclear transport of influenza virus ribonucleoproteins","volume":"70","author":"Bui","year":"1996","journal-title":"J Virol."},{"key":"10.1016\/j.arbres.2016.07.004_bib0760","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1021\/bi027176t","article-title":"Zinc- and pH-dependent conformational transition in a putative interdomain linker region of the influenza virus matrix protein M1","volume":"42","author":"Okada","year":"2003","journal-title":"Biochemistry."},{"key":"10.1016\/j.arbres.2016.07.004_bib0765","doi-asserted-by":"crossref","first-page":"13029","DOI":"10.1128\/JVI.01430-14","article-title":"Stepwise priming by acidic pH and a high K+ concentration is required for efficient uncoating of influenza A virus cores after penetration","volume":"88","author":"Stauffer","year":"2014","journal-title":"J Virol."},{"key":"10.1016\/j.arbres.2016.07.004_bib0770","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/nar\/6.4.1221","article-title":"Polyadenylation and reverse transcription of influenza viral RNA","volume":"6","author":"Emtage","year":"1979","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.arbres.2016.07.004_bib0775","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.virusres.2004.08.012","article-title":"Assembly and budding of influenza virus","volume":"106","author":"Nayak","year":"2004","journal-title":"Virus Res."},{"key":"10.1016\/j.arbres.2016.07.004_bib0780","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1752-0509-7-97","article-title":"A comprehensive map of the influenza A virus replication cycle","volume":"7","author":"Matsuoka","year":"2013","journal-title":"BMC Syst Biol."},{"key":"10.1016\/j.arbres.2016.07.004_bib0785","unstructured":"U. S. Food and Drug Administration. Drugs [consultado 28 Abr 2016]. Disponible en: www.fda.gob\/drugs"},{"key":"10.1016\/j.arbres.2016.07.004_bib0790","unstructured":"Centers for Disease Control and Prevention. Influenza (Flu) [consultado 28 Abr 2016]. Disponible en: http:\/\/www.cdc.gov\/flu"},{"key":"10.1016\/j.arbres.2016.07.004_bib0795","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nature06531","article-title":"Structure and mechanism of the M2 proton channel of influenza A virus","volume":"451","author":"Schnell","year":"2008","journal-title":"Nature."},{"key":"10.1016\/j.arbres.2016.07.004_bib0800","doi-asserted-by":"crossref","first-page":"11525","DOI":"10.1073\/pnas.88.24.11525","article-title":"Amantadine selection of a mutant influenza virus containing an acid-stable hemagglutinin glycoprotein: Evidence for virus-specific regulation of the pH of glycoprotein transport vesicles","volume":"88","author":"Steinhauer","year":"1991","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.arbres.2016.07.004_bib0805","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.bmc.2009.11.047","article-title":"Synthesis and anti-viral activity of azolo-adamantanes against influenza A virus","volume":"18","author":"Zarubaev","year":"2010","journal-title":"Bioorg Med Chem."},{"key":"10.1016\/j.arbres.2016.07.004_bib0810","doi-asserted-by":"crossref","first-page":"17987","DOI":"10.1021\/ja508461m","article-title":"Flipping in the pore: Discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant S31N mutant of the influenza A virus M2 proton channel","volume":"136","author":"Wu","year":"2014","journal-title":"J Am Chem Soc."},{"key":"10.1016\/j.arbres.2016.07.004_bib0815","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0166-3542(97)00065-X","article-title":"Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor","volume":"37","author":"Sidwell","year":"1998","journal-title":"Antiviral Res."},{"key":"10.1016\/j.arbres.2016.07.004_bib0820","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2015.02.003","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014","volume":"117","author":"Takashita","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.arbres.2016.07.004_bib0825","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1128\/AAC.46.4.1014-1021.2002","article-title":"In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication","volume":"46","author":"Kati","year":"2002","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.arbres.2016.07.004_bib0830","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.antiviral.2007.08.008","article-title":"Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes","volume":"77","author":"Abed","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.arbres.2016.07.004_bib0835","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejmech.2015.12.031","article-title":"Design, synthesis, and biological evaluation of crenatoside analogues as novel influenza neuraminidase inhibitors","volume":"109","author":"Chen","year":"2016","journal-title":"Eur J Med Chem."},{"key":"10.1016\/j.arbres.2016.07.004_bib0840","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ardp.201500209","article-title":"Design, synthesis, and molecular docking of novel pyrrolooxazepinediol derivatives with anti-influenza neuraminidase activity","volume":"348","author":"El-Nezhawy","year":"2015","journal-title":"Arch Pharm (Weinheim)."},{"key":"10.1016\/j.arbres.2016.07.004_bib0845","doi-asserted-by":"crossref","first-page":"g2545","DOI":"10.1136\/bmj.g2545","article-title":"Oseltamivir for influenza in adults and children: Systematic review of clinical study reports and summary of regulatory comments","volume":"348","author":"Jefferson","year":"2014","journal-title":"BMJ."},{"key":"10.1016\/j.arbres.2016.07.004_bib0850","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(14)62449-1","article-title":"Oseltamivir treatment for influenza in adults: A meta-analysis of randomised controlled trials","volume":"385","author":"Dobson","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.arbres.2016.07.004_bib0855","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1086\/656316","article-title":"Effectiveness of antiviral treatment in human influenza A(H5N1) infections: Analysis of a Global Patient Registry","volume":"202","author":"Adisasmito","year":"2010","journal-title":"J Infect Dis."},{"key":"10.1016\/j.arbres.2016.07.004_bib0860","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/thx.2009.130799","article-title":"Outcomes of adults hospitalised with severe influenza","volume":"65","author":"Lee","year":"2010","journal-title":"Thorax."},{"key":"10.1016\/j.arbres.2016.07.004_bib0865","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/523584","article-title":"Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada","volume":"45","author":"McGeer","year":"2007","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.arbres.2016.07.004_bib0870","unstructured":"PHE guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza (2015-16). Version 6.0, September 2015 [consultado 28 Abr 2016]. Disponible en: www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/457735\/PHE_guidance_antivirals_influenza_2015_to_2016.pdf"},{"key":"10.1016\/j.arbres.2016.07.004_bib0875","series-title":"WHO guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses","year":"2010"},{"key":"10.1016\/j.arbres.2016.07.004_bib0880","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1128\/JVI.01225-13","article-title":"New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusion","volume":"88","author":"Basu","year":"2014","journal-title":"J Virol."},{"key":"10.1016\/j.arbres.2016.07.004_bib0885","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1021\/jm1002183","article-title":"Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy","volume":"53","author":"Matsubara","year":"2010","journal-title":"J Med Chem."},{"key":"10.1016\/j.arbres.2016.07.004_bib0890","doi-asserted-by":"crossref","first-page":"e0138426","DOI":"10.1371\/journal.pone.0138426","article-title":"New influenza A virus entry inhibitors derived from the viral fusion peptides","volume":"10","author":"Wu","year":"2015","journal-title":"PLoS One."},{"key":"10.1016\/j.arbres.2016.07.004_bib0895","doi-asserted-by":"crossref","first-page":"e15874","DOI":"10.1371\/journal.pone.0015874","article-title":"Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol","volume":"6","author":"Teissier","year":"2011","journal-title":"PLoS One."},{"key":"10.1016\/j.arbres.2016.07.004_bib0900","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF00772858","article-title":"Synthesis of a new antiviral agent, arbidole","volume":"27","author":"Trofimov","year":"1993","journal-title":"Pharm Chem J"},{"key":"10.1016\/j.arbres.2016.07.004_bib0905","doi-asserted-by":"crossref","first-page":"88","DOI":"10.17116\/terarkh201587188-96","article-title":"[Clinical efficacy of arbidol (umifenovir) in the therapy of influenza in adults: Preliminary results of the multicenter double-blind randomized placebo-controlled study ARBITR] Russian","volume":"87","author":"Kiselev","year":"2015","journal-title":"Ter Arkh."},{"key":"10.1016\/j.arbres.2016.07.004_bib0910","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2008.10.009","article-title":"Characteristics of arbidol-resistant mutants of influenza virus: Implications for the mechanism of anti-influenza action of arbidol","volume":"81","author":"Leneva","year":"2009","journal-title":"Antiviral Res."},{"key":"10.1016\/j.arbres.2016.07.004_bib0915","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.antiviral.2013.05.005","article-title":"Design of inhibitors of influenza virus membrane fusion: Synthesis, structure-activity relationship and in vitro antiviral activity of a novel indole series","volume":"99","author":"Brancato","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.arbres.2016.07.004_bib0920","doi-asserted-by":"crossref","first-page":"14216","DOI":"10.1073\/pnas.1111497108","article-title":"Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin","volume":"108","author":"Whittle","year":"2011","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.arbres.2016.07.004_bib0925","doi-asserted-by":"crossref","first-page":"6743","DOI":"10.1128\/JVI.03562-13","article-title":"A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head","volume":"88","author":"Benjamin","year":"2014","journal-title":"J Virol."},{"key":"10.1016\/j.arbres.2016.07.004_bib0930","doi-asserted-by":"crossref","first-page":"e1005409","DOI":"10.1371\/journal.ppat.1005409","article-title":"A computationally designed hemagglutinin stem-binding protein provides in vivo protection from influenza independent of a host immune response","volume":"12","author":"Koday","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.arbres.2016.07.004_bib0935","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.arbres.2016.07.004_bib0940","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1073\/pnas.0909603107","article-title":"T-705 (favipiravir) activity against lethal H5N1 influenza A viruses","volume":"107","author":"Kiso","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.arbres.2016.07.004_bib0945","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.00933-09","article-title":"Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice","volume":"54","author":"Smee","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.arbres.2016.07.004_bib0950","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.antiviral.2012.03.001","article-title":"Combinations of favipiravir and peramivir for the treatment of pandemic influenza A\/California\/04\/2009 (H1N1) virus infections in mice","volume":"94","author":"Tarbet","year":"2012","journal-title":"Antiviral Res."},{"key":"10.1016\/j.arbres.2016.07.004_bib0955","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1128\/JVI.69.7.3995-3999.1995","article-title":"Differential activation of the influenza virus polymerase via template RNA binding","volume":"69","author":"Cianci","year":"1995","journal-title":"J Virol."},{"key":"10.1016\/j.arbres.2016.07.004_bib0960","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1128\/JVI.32.3.895-904.1979","article-title":"Cap and internal nucleotides of reovirus mRNA primers are incorporated into influenza viral complementary RNA during transcription in vitro","volume":"32","author":"Bouloy","year":"1979","journal-title":"J Virol."},{"issue":"Pt 2","key":"10.1016\/j.arbres.2016.07.004_bib0965","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1107\/S2059798316000085","article-title":"The cap-binding site of influenza virus protein PB2 as a drug target","volume":"72","author":"Severin","year":"2016","journal-title":"Acta Crystallogr D Struct Biol."},{"key":"10.1016\/j.arbres.2016.07.004_bib0970","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1021\/jm5007275","article-title":"Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem."},{"key":"10.1016\/j.arbres.2016.07.004_bib0975","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1128\/AAC.04623-14","article-title":"Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit","volume":"59","author":"Byrn","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"issue":"Pt 4","key":"10.1016\/j.arbres.2016.07.004_bib0980","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1099\/0022-1317-83-4-723","article-title":"The influenza virus nucleoprotein: A multifunctional RNA-binding protein pivotal to virus replication","volume":"83","author":"Portela","year":"2002","journal-title":"J Gen Virol."},{"key":"10.1016\/j.arbres.2016.07.004_bib0985","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1128\/JVI.03123-12","article-title":"Nucleozin targets cytoplasmic trafficking of viral ribonucleoprotein-Rab11 complexes in influenza A virus infection","volume":"87","author":"Amorim","year":"2013","journal-title":"J Virol."},{"key":"10.1016\/j.arbres.2016.07.004_bib0990","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1021\/jm2013503","article-title":"Design, synthesis, and in vitro biological evaluation of 1H-1,2,3-triazole-4-carboxamide derivatives as new anti-influenza A agents targeting virus nucleoprotein","volume":"55","author":"Cheng","year":"2012","journal-title":"J Med Chem."},{"key":"10.1016\/j.arbres.2016.07.004_bib0995","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1128\/AAC.02335-12","article-title":"Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus","volume":"57","author":"Lejal","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.arbres.2016.07.004_bib1000","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1080\/07391102.2014.979230","article-title":"Structure-based design of novel naproxen derivatives targeting monomeric nucleoprotein of Influenza A virus","volume":"33","author":"Tarus","year":"2015","journal-title":"J Biomol Struct Dyn."},{"issue":"Pt 12","key":"10.1016\/j.arbres.2016.07.004_bib1005","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1099\/0022-1317-73-12-3325","article-title":"Binding of influenza A virus NS1 protein to dsRNA in vitro","volume":"73","author":"Hatada","year":"1992","journal-title":"J Gen Virol."},{"key":"10.1016\/j.arbres.2016.07.004_bib1010","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1006\/viro.1995.9937","article-title":"Binding of the influenza virus NS1 protein to double-stranded RNA inhibits the activation of the protein kinase that phosphorylates the elF-2 translation initiation factor","volume":"214","author":"Lu","year":"1995","journal-title":"Virology."},{"key":"10.1016\/j.arbres.2016.07.004_bib1015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1101\/gad.6.2.255","article-title":"Nucleocytoplasmic transport: The influenza virus NS1 protein regulates the transport of spliced NS2 mRNA and its precursor NS1 mRNA","volume":"6","author":"Alonso-Caplen","year":"1992","journal-title":"Genes Dev."},{"key":"10.1016\/j.arbres.2016.07.004_bib1020","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/j.1460-2075.1994.tb06310.x","article-title":"Influenza virus NS1 protein inhibits pre-mRNA splicing and blocks mRNA nucleocytoplasmic transport","volume":"13","author":"Fortes","year":"1994","journal-title":"EMBO J."},{"key":"10.1016\/j.arbres.2016.07.004_bib1025","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1128\/JVI.68.4.2425-2432.1994","article-title":"The influenza virus NS1 protein is a poly(A)-binding protein that inhibits nuclear export of mRNAs containing poly(A)","volume":"68","author":"Qiu","year":"1994","journal-title":"J Virol."},{"key":"10.1016\/j.arbres.2016.07.004_bib1030","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1006\/viro.1998.9508","article-title":"Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems","volume":"252","author":"Garc\u00eda-Sastre","year":"1998","journal-title":"Virology."},{"key":"10.1016\/j.arbres.2016.07.004_bib1035","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.chom.2009.04.006","article-title":"Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I","volume":"5","author":"Gack","year":"2009","journal-title":"Cell Host Microbe."},{"key":"10.1016\/j.arbres.2016.07.004_bib1040","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1128\/JVI.02843-15","article-title":"The role of N-terminus-truncated NS1 proteins of influenza A virus in inhibiting IRF3 activation","volume":"90","author":"Kuo","year":"2016","journal-title":"J Virol."},{"key":"10.1016\/j.arbres.2016.07.004_bib1045","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1128\/JVI.01805-08","article-title":"Novel influenza virus NS1 antagonists block replication and restore innate immune function","volume":"83","author":"Basu","year":"2009","journal-title":"J Virol."},{"key":"10.1016\/j.arbres.2016.07.004_bib1050","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.bmc.2011.10.026","article-title":"Design, synthesis, and evaluation of novel small molecule inhibitors of the influenza virus protein NS1","volume":"20","author":"Jablonski","year":"2012","journal-title":"Bioorg Med Chem."},{"issue":"Pt 1","key":"10.1016\/j.arbres.2016.07.004_bib1055","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1099\/vir.0.025015-0","article-title":"Novel inhibitor of influenza non-structural protein 1 blocks multi-cycle replication in an RNase L-dependent manner","volume":"92","author":"Walkiewicz","year":"2011","journal-title":"J Gen Virol."},{"key":"10.1016\/j.arbres.2016.07.004_bib1060","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/jac\/dkt534","article-title":"Antiviral activity of baicalin against influenza virus H1N1-pdm09 is due to modulation of NS1-mediated cellular innate immune responses","volume":"69","author":"Nayak","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.arbres.2016.07.004_bib1065","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.cell.2009.12.018","article-title":"A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection","volume":"139","author":"Shapira","year":"2009","journal-title":"Cell."},{"key":"10.1016\/j.arbres.2016.07.004_bib1070","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.chom.2014.11.002","article-title":"Influenza virus-host interactome screen as a platform for antiviral drug development","volume":"16","author":"Watanabe","year":"2014","journal-title":"Cell Host Microbe."},{"key":"10.1016\/j.arbres.2016.07.004_bib1075","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1039\/c2mb05416g","article-title":"Genetic screens for the control of influenza virus replication: From meta-analysis to drug discovery","volume":"8","author":"De Chassey","year":"2012","journal-title":"Mol Biosyst."},{"key":"10.1016\/j.arbres.2016.07.004_bib1080","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1093\/infdis\/jis622","article-title":"A phase ii study of DAS181, a novel host directed antiviral for the treatment of influenza infection","volume":"206","author":"Moss","year":"2012","journal-title":"J Infect Dis."},{"key":"10.1016\/j.arbres.2016.07.004_bib1085","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1128\/AAC.50.4.1470-1479.2006","article-title":"Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection","volume":"50","author":"Malakhov","year":"2006","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.arbres.2016.07.004_bib1090","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3851\/IMP1715","article-title":"Aprotinin, a protease inhibitor, suppresses proteolytic activation of pandemic H1N1v influenza virus","volume":"21","author":"Zhirnov","year":"2011","journal-title":"Antivir Chem Chemother."},{"key":"10.1016\/j.arbres.2016.07.004_bib1095","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0166-3542(94)90038-8","article-title":"Aprotinin aerosol treatment of influenza and paramyxovirus bronchopneumonia of mice","volume":"23","author":"Ovcharenko","year":"1994","journal-title":"Antiviral Res."},{"key":"10.1016\/j.arbres.2016.07.004_bib1100","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1042\/BJ20130101","article-title":"Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation","volume":"452","author":"Meyer","year":"2013","journal-title":"Biochem J."},{"key":"10.1016\/j.arbres.2016.07.004_bib1105","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1085\/jgp.112.4.409","article-title":"Effects of spontaneous bilayer curvature on influenza virus-mediated fusion pores","volume":"112","author":"Razinkov","year":"1998","journal-title":"J Gen Physiol."},{"issue":"Pt 1","key":"10.1016\/j.arbres.2016.07.004_bib1110","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1042\/BJ20051069","article-title":"The broad anti-viral agent glycyrrhizin directly modulates the fluidity of plasma membrane and HIV-1 envelope","volume":"392","author":"Harada","year":"2005","journal-title":"Biochem J."},{"key":"10.1016\/j.arbres.2016.07.004_bib1115","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.antiviral.2009.04.012","article-title":"Glycyrrhizin inhibits influenza A virus uptake into the cell","volume":"83","author":"Wolkerstorfer","year":"2009","journal-title":"Antiviral Res."},{"key":"10.1016\/j.arbres.2016.07.004_bib1120","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1073\/pnas.0909587107","article-title":"A broad-spectrum antiviral targeting entry of enveloped viruses","volume":"107","author":"Wolf","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.arbres.2016.07.004_bib1125","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1128\/JVI.69.4.2306-2312.1995","article-title":"Requirement for vacuolar proton-ATPase activity during entry of influenza virus into cells","volume":"69","author":"Guinea","year":"1995","journal-title":"J Virol."},{"key":"10.1016\/j.arbres.2016.07.004_bib1130","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0166-3542(95)00040-S","article-title":"Inhibitory effect of bafilomycin A1, a specific inhibitor of vacuolar-type proton pump, on the growth of influenza A and B viruses in MDCK cells","volume":"27","author":"Ochiai","year":"1995","journal-title":"Antiviral Res."},{"key":"10.1016\/j.arbres.2016.07.004_bib1135","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1476-5381.2011.01346.x","article-title":"The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections","volume":"164","author":"Muller","year":"2011","journal-title":"Br J Pharmacol."},{"key":"10.1016\/j.arbres.2016.07.004_bib1140","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.chom.2007.06.009","article-title":"The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts","volume":"2","author":"Wang","year":"2007","journal-title":"Cell Host Microbe."},{"key":"10.1016\/j.arbres.2016.07.004_bib1145","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1128\/JVI.01917-06","article-title":"Involvement of Hsp90 in assembly and nuclear import of influenza virus RNA polymerase subunits","volume":"81","author":"Naito","year":"2007","journal-title":"J Virol."},{"key":"10.1016\/j.arbres.2016.07.004_bib1150","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.virol.2008.04.040","article-title":"Hsp90 inhibitors reduce influenza virus replication in cell culture","volume":"377","author":"Chase","year":"2008","journal-title":"Virology."},{"key":"10.1016\/j.arbres.2016.07.004_bib1155","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1073\/pnas.70.4.1174","article-title":"Mechanism of action of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent","volume":"70","author":"Streeter","year":"1973","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.arbres.2016.07.004_bib1160","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1749-6632.1977.tb21959.x","article-title":"Aerosol therapy of influenza infections of mice and primates with rimantadine, ribavirin, and related compounds","volume":"284","author":"Stephen","year":"1977","journal-title":"Ann N Y Acad Sci."},{"issue":"Suppl","key":"10.1016\/j.arbres.2016.07.004_bib1165","doi-asserted-by":"crossref","first-page":"A114","DOI":"10.1093\/infdis\/133.Supplement_2.A114","article-title":"Comparative clinical and laboratory evaluation of the prophylactic capacity of ribavirin, amantadine hydrochloride, and placebo in induced human influenza type A","volume":"133","author":"Cohen","year":"1976","journal-title":"J Infect Dis."},{"key":"10.1016\/j.arbres.2016.07.004_bib1170","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0022-3476(94)70139-3","article-title":"Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: A double-blind, multicenter, placebo-controlled trial","volume":"125","author":"Rodriguez","year":"1994","journal-title":"J Pediatr."},{"key":"10.1016\/j.arbres.2016.07.004_bib1175","doi-asserted-by":"crossref","first-page":"10228","DOI":"10.1128\/JVI.01774-14","article-title":"Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza A virus replication in vitro and in vivo","volume":"88","author":"Perwitasari","year":"2014","journal-title":"J Virol."},{"key":"10.1016\/j.arbres.2016.07.004_bib1180","doi-asserted-by":"crossref","first-page":"29798","DOI":"10.1074\/jbc.M109.029470","article-title":"Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level","volume":"284","author":"Rossignol","year":"2009","journal-title":"J Biol Chem."},{"key":"10.1016\/j.arbres.2016.07.004_bib1185","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1473-3099(14)70717-0","article-title":"Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: A double-blind, randomised, placebo-controlled, phase 2b\/3 trial","volume":"14","author":"Haffizulla","year":"2014","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.arbres.2016.07.004_bib1190","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/35060098","article-title":"Influenza virus propagation is impaired by inhibition of the Raf\/MEK\/ERK signalling cascade","volume":"3","author":"Pleschka","year":"2001","journal-title":"Nat Cell Biol."},{"key":"10.1016\/j.arbres.2016.07.004_bib1195","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0014-5793(04)00108-5","article-title":"MEK inhibition impairs influenza B virus propagation without emergence of resistant variants","volume":"561","author":"Ludwig","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.arbres.2016.07.004_bib1200","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.antiviral.2011.08.002","article-title":"Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo","volume":"92","author":"Droebner","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.arbres.2016.07.004_bib1205","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.antiviral.2013.03.006","article-title":"Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro","volume":"98","author":"Haasbach","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.arbres.2016.07.004_bib1210","doi-asserted-by":"crossref","first-page":"30931","DOI":"10.1074\/jbc.M403258200","article-title":"NF-kappaB-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas\/FasL is crucial for efficient influenza virus propagation","volume":"279","author":"Wurzer","year":"2004","journal-title":"J Biol Chem."},{"issue":"Pt 8","key":"10.1016\/j.arbres.2016.07.004_bib1215","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1099\/vir.0.79958-0","article-title":"Active NF-kappaB signalling is a prerequisite for influenza virus infection","volume":"85","author":"Nimmerjahn","year":"2004","journal-title":"J Gen Virol."},{"key":"10.1016\/j.arbres.2016.07.004_bib1220","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1111\/j.1462-5822.2007.00902.x","article-title":"Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity","volume":"9","author":"Mazur","year":"2007","journal-title":"Cell Microbiol."},{"key":"10.1016\/j.arbres.2016.07.004_bib1225","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.virol.2007.05.001","article-title":"Inhibitors of the sodium potassium ATPase that impair herpes simplex virus replication identified via a chemical screening approach","volume":"366","author":"Dodson","year":"2007","journal-title":"Virology."},{"key":"10.1016\/j.arbres.2016.07.004_bib1230","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1128\/AAC.00898-12","article-title":"Human cytomegalovirus inhibition by cardiac glycosides: Evidence for involvement of the HERG gene","volume":"56","author":"Kapoor","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.arbres.2016.07.004_bib1235","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1021\/pr500556d","article-title":"Elucidation of the Ebola virus VP24 cellular interactome and disruption of virus biology through targeted inhibition of host-cell protein function","volume":"13","author":"Garc\u00eda-Dorival","year":"2014","journal-title":"J Proteome Res."},{"key":"10.1016\/j.arbres.2016.07.004_bib1240","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1128\/JVI.03274-14","article-title":"ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells","volume":"89","author":"Burkard","year":"2015","journal-title":"J Virol."},{"key":"10.1016\/j.arbres.2016.07.004_bib1245","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.virol.2015.04.025","article-title":"Conformational changes required for reovirus cell entry are sensitive to pH","volume":"483","author":"Thete","year":"2015","journal-title":"Virology."},{"key":"10.1016\/j.arbres.2016.07.004_bib1250","doi-asserted-by":"crossref","first-page":"13392","DOI":"10.1128\/JVI.00770-07","article-title":"Identification of novel antipoxviral agents: Mitoxantrone inhibits vaccinia virus replication by blocking virion assembly","volume":"81","author":"Deng","year":"2007","journal-title":"J Virology."},{"key":"10.1016\/j.arbres.2016.07.004_bib1255","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.antiviral.2008.05.008","article-title":"Modulation of influenza virus replication by alteration of sodium ion transport and protein kinase C activity","volume":"80","author":"Hoffmann","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.arbres.2016.07.004_bib1260","article-title":"The cardioactive glycoside ouabain inhibits influenza A viral replication","volume":"189","author":"Katzen","year":"2014","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289616302058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289616302058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T23:19:17Z","timestamp":1601075957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289616302058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":126,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0300289616302058"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2016.07.004","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tratamiento antigripal: f\u00e1rmacos actualmente utilizados y nuevos agentes en desarrollo","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2016.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}